---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-011723"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-06-16T23:59:59+00:00"
generated_at: "2026-06-25T01:20:17.061176+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics stockholders elect three Class I directors and ratify Deloitte as auditor

## Summary
- 36,785,341 shares (77.35% of outstanding) present at June 10, 2022 annual meeting.
- Domenic Ferrante, Nicholas Haft, Samuel A. Hamood elected as Class I directors with >26.8M votes for each.
- Ratification of Deloitte & Touche as auditor for FY2022 approved: 36,759,831 for, 20,585 against.
- Broker non-votes of 7,987,710 on director election; none on auditor ratification.

## SEC filing metadata
- accession: 0000950170-22-011723
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-06-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022011723/0000950170-22-011723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022011723/fnch-20220610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-011723
- JSON: https://secwatch.observer/filing/0000950170-22-011723.json
- Plain text: https://secwatch.observer/filing/0000950170-22-011723.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.